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Edited by Hans EklundAbstract The natural cofactor of phenylalanine hydroxylase
(PAH), tetrahydrobiopterin (BH4), regulates the enzyme activity
as well as being essential in catalysis. BH4-responsive PAH
deﬁciency is a variant of hyperphenylalaninemia or phenylke-
tonuria (PKU) caused by mutations in the human PAH gene that
respond to oral BH4 loading by stimulating enzyme activity and
therefore lowering serum phenylalanine. Here, we showed in a
coupled transcription–translation in vitro assay that upon
expression in the presence of BH4, wild-type PAH enzyme
activity was enhanced. We then investigated the eﬀect of BH4 on
PAH activity in transgenic mice that had a complete or partial
deﬁciency in the endogenous cofactor biosynthesis. The rate of
hepatic PAH enzyme activity increased signiﬁcantly with BH4
content without aﬀecting gene expression or Pah-mRNA stabil-
ity. These results indicate that BH4 has a chaperon-like eﬀect on
PAH synthesis and/or is a protecting cofactor against enzyme
auto-inactivation and degradation also in vivo. Our ﬁndings thus
contribute to the understanding of the regulation of PAH by its
cofactor BH4 on an additional level and provide a molecular
explanation for cofactor-responsive PKU.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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As an essential oxygen-activating cofactor for nitric oxide
synthase (NOS) and aromatic amino acid hydroxylases, tet-
rahydrobiopterin (BH4) is necessary for NO and monoamine
neurotransmitter production, as well as for phenylalanine ca-
tabolism. Other functions associated with BH4, some of which
are less deﬁned on a molecular level, include regulation of cell
proliferation, self-protecting activity for NO toxicity, and
regulation of apoptosis [1,2]. Most of these eﬀects are sec-
ondary and can be attributed to either the intracellular avail-
ability of BH4 for NO production or superoxide/peroxide
formation from auto-oxidation of non-protein-bound BH4 in
the presence of molecular oxygen [3]. Although the enzymes
involved in the synthesis of BH4 are constitutively expressed in* Corresponding author. Fax: +41-1-266-7169.
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doi:10.1016/j.febslet.2004.10.056liver (but not necessarily in other organs), where BH4 acts as
cofactor of the enzyme phenylalanine hydroxylase (PAH), the
regulation of the BH4 biosynthesis is complex. BH4 negatively
regulates its synthesis by product feedback inhibition of the
ﬁrst enzyme in the synthesis pathway, the GTP cyclohydrolase
I, while L-Phe is an activator [1]. BH4 also exerts direct neg-
ative regulatory eﬀects on the activity of the hepatic PAH,
namely as an inhibitor of both the activation of the enzyme by
preincubation with L-Phe [4] and of the rate of phosphoryla-
tion of the enzyme [5]. Moreover, in vitro, BH4 inhibits the
proteolytic degradation of PAH [6], but little is known about
the in vivo signiﬁcance of these ﬁndings or the regulation of
PAH by BH4 at the transcriptional and translational level.
Synthetic BH4 is routinely used for replacement therapy to
treat patients with one of the rare genetic defects of cofactor
biosynthesis or regeneration [7]. Recently, a potential new
application for BH4 was put forward. This concerns the BH4-
responsive PAH deﬁciency [8,9], which is a subtype of classical
phenylketonuria (PKU; for a recent review see also [10]). PKU
is an autosomal recessive disorder and over 400 mutations
have been reported causing various degrees of deﬁciency in
hepatic PAH, and thus to abnormal and toxic accumulation of
serum L-Phe [11]. PKU patients that respond to high doses of
oral synthetic BH4 carry speciﬁc mutations in the human PAH
gene leading to either single amino acid alterations or small in-
frame insertions or deletions. All these responsive mutant al-
leles exhibit potential residual PAH activity [12]. Based on the
known 3D-structure for the tetrameric PAH and on the loca-
tion or vicinity of mutations to the catalytic domain including
the BH4-binding site, or the regulatory or oligomerization
domains, it has been proposed that the responsiveness to BH4
is related to Km variants with lowered aﬃnity for BH4 binding
[13–16]. However, for BH4-responsiveness of PAH-mutations
found outside these domains, alternative explanations were
discussed, including upregulation of gene expression, PAH-
mRNA stabilization, and protection of PAH from misfolding
and/or degradation [17–20]. Recent experimental analyses of
wild-type or mutant PAH indicated that the response of PKU
mutations may have a multifactorial basis [21].
The generation of 6-pyruvoyltetrahydropterin synthase (Pts)
knockout mice, which are unable to biosynthesize BH4, has
recently been described [22,23]. Interestingly, the Pts= ho-
mozygotes showed normal tyrosine hydroxylase (TH) gene
expression, as shown by Northern blot analysis of brain tissue,
but a depletion of protein and activity with respect to theation of European Biochemical Societies.
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not aﬀected [22]. Furthermore, blood phenylalanine content
was increased in Pts= mice [23]. However, the consequence of
disruption of the Pts gene on PAH protein and activity has not
been investigated in detail. Here, we have analyzed the eﬀect of
BH4 on wild-type PAH expression and activity in untreated
newborn mice in the Pts k.o., heterozygous, and wild-type
background, and found that the natural cofactor for PAH
does not aﬀect gene expression but rather stimulates PAH
enzyme activity and stability in a concentration-dependent
manner, thus providing a rationale for BH4-responsive hy-
perphenylalaninemia in humans.2. Materials and methods
2.1. Coupled in vitro transcription–translation system
Coupled in vitro transcription–translation (TnT) of wild-type hu-
man PAH was carried out by using the TnT-T7 reticulocyte lysate
system from Promega and the pcDNA3-hPAH expression vector as
described [24], with various concentrations of added BH4 up to 500
lM, kept reduced with 5 mM dithiothreitol, which was also present in
the synthesis assays carried out in the absence of BH4. After 30 min,
the extracts were ﬁltrated with MicroSpinTM G-25 columns (Amer-
sham Biosciences) to eliminate free amino acids, BH4 and other low
molecular weight compounds prior to measurements of PAH activity
at standard conditions using 15 ll of the ﬁltrated extract.
2.2. Transgenic Pts mice
Hybrid mice from 129/Sv-C57BL/6 back-crossings with diﬀerent
genotypes regarding the Pts allele (wild-type, heterozygous and ho-
mozygous; 3–8 individuals from each group) were sacriﬁced at day one
after birth and their livers were frozen immediately in liquid nitrogen.
Liver homogenate was prepared at 4 C in the presence of dithio-
threitol and the protease inhibitors phenylmethylsulfonyl ﬂuoride,
leupeptin, and pepstatin as described [23].
2.3. Assay of PAH activity
ThePAHactivity assaywas adapted fromLedleay et al. [25]. For every
assay, liver homogenate containing 50–100 lg of total protein was used
[23]. The appropriate amount of homogenate was adjusted to a ﬁnal
volume of 78 ll with water, followed by adding 22 ll of a master mix
containing 0.6mMphenylalanine, 3.6Uof catalase (Sigma), and 0.15M
KCl in a 0.2Mpotassiumphosphate buﬀer, pH 6.8. After preincubation
at room temperature for 5min, the reactionwas started by adding 2 ll of
0.1 M dithiothreitol and 2 ll of 4.5 mM 6-methyltetrahydropterin
(SchircksLaboratories) to the samples and incubated for 60min at 25 C.
The reaction was stopped by incubating for 5 min a 96 C heating block.
For the blank, the appropriate amount of liver extract was adjusted to a
ﬁnal volume of 104 ll with water and incubated for 5 min in a 96 C
heating block. Sampleswere centrifuged for 5min at 13 000 rpm, and the
supernatantwas ﬁltered in anUltrafree-MCﬁlter device and centrifuged
again at 5000 g for 15min. Phenylalanine and tyrosine were quantiﬁed
with a standard amino acid analyzer (Biochrom 20 Plus, Amersham
Bioscienes). Alternatively, for the measurement of PAH in the TnT ex-
pression assays (see above), wemeasured activity as described [26], using
standard concentrations ofL-Phe (1mM)andBH4 (75lM; (6R)-5,6,7,8-
tetrahydro-L-biopterin, BH42HCl from Schircks Laboratories, Jona,
Switzerland) at pH 7.0 and 25 C, with pre-activation of the enzyme by 5
min pre-incubation with L-Phe.
2.4. Western blot analysis
Quantiﬁcation of hepatic PAH by Western blot analysis was per-
formed as described [26], using aﬃnity-puriﬁed polyclonal rabbit anti-
rat PAH (1.6 lg/ml) as the primary antibody, and 3–100 ng human
PAH protein, in which range the method was quantitatively linear.
2.5. RNA isolation and quantitative PCR
20–30 mg of mouse liver was used for RNA isolation according to
the manufacturer’s protocol (QIAmp RNA Blood Mini Kit from
Qiagen). Random primed cDNA was prepared from 1 lg total RNA
using the Reverse Transcription System from Promega. QuantitativePCR was performed using Taqman technology and an AbiPrism 7700
sequence detector and the TaqMan Universal PCR Master Mix (Ap-
plied Biosystems). Probe and primer sequences were as follows:
MPAH3-TM-Probe: 50-CTT TTG CTG CCA CAA TCC CCC G-30
(50-FAM and 30-TAMRA-labeled); MPAH1-TM-FOR: 50-CCG AGA
GTT TCA ATG ATG CCA-30; MPAH2-TM-REV: 50-TCA TAG
CGA ACG GAG AAG GG-30. For controls, standard probes for
GAPDH or 18S ribosomal RNA were used. All probes and sequences
were synthesized by Microsynth (Balgach, Switzerland).3. Results and discussion
3.1. BH4 enhances PAH activity under in vitro conditions
Recently, pulse-chase analyses in a cell-free coupled TnT
eukaryote system have been applied to investigate the eﬀect of
BH4 on the activity and stability of PAH expressed in the
absence and the presence of BH4 [21]. As seen by size-exclusion
chromatography, the in vitro synthesized protein has a similar
oligomeric distribution into tetrameric and dimeric forms as
the enzyme from liver or obtained by expression in Escherichia
coli [27] both in the absence and the presence of BH4 during
synthesis [21]. Nevertheless, the presence of the cofactor results
in a moderate stimulation of the activity of the newly synthe-
sized PAH, and also appears to protect the enzyme against the
rapid inactivation observed in the TnT system, possibly by
shielding the active site from reactive oxygen species [21].
These experiments, however, were performed at very high
concentration of BH4 (500 lM), far above the physiological
intracellular concentration of BH4 in mouse and human liver,
which have been reported to be 5 and 10 lM, respectively
[21,28,29]. We here studied the synthesis of [35S]Met-labeled
PAH in the TnT system for 30 min at 30 C in the presence of
various concentrations of BH4 up to 500 lM. The in vitro
synthesized enzyme showed the characteristic double band
corresponding to the phosphorylated (51 kDa) and un-
phosphorylated (50 kDa) enzyme (Fig. 1A). The amount of
protein was found to increase slightly with BH4 concentration
up to 100 lM BH4 (maximal 22 3% increase in total protein
content), and no change was observed in the similar distribu-
tion of phosphorylated and unphosphorylated PAH (Fig. 1A).
The speciﬁc activity of the synthesized PAH measured at
standard conditions (1 mM L-Phe and 75 lM BH4) increased
more signiﬁcantly than the protein amount when expression
was carried out in the presence of BH4, with an optimum range
for BH4 at 25–100 lM under the conditions used (Fig. 1B).
The stimulation by BH4 of PAH activity expressed in vitro is
most probably related to a direct eﬀect on the enzyme, since
activation of transcription or mRNA stabilization can be ruled
out in this in vitro protein expression system. Moreover, ac-
cording to some recent results based on TnT assays combined
with pulse-chase methodology [21], we anticipate increased
amount of protein, and consequently of activity, for a number
of PAH mutant proteins in PKU patients, such as A309V,
V388M, and Y414C, for which it was observed in vitro that
BH4 prevents protein degradation (see also the discussion be-
low on sub-saturating levels of BH4 with respect to PAH).
3.2. Newborn mice defective for BH4-cofactor biosynthesis
exhibit normal PAH gene expression but reduced protein
and enzyme activity
To our knowledge, no animal model with a BH4-responsive
mutant PAH is available to investigate the eﬀect of BH4 on
Fig. 1. Eﬀect of BH4 on the expression of wild-type human PAH in the in vitro TnT system. (A) Lanes 1–7: autoradiography of the expressed enzyme,
phosphorylated (PAH-phos; 51 kDa) and unphosphorylated (PAH; 50 kDa) in the presence of 0, 5, 10, 25, 100, 250, and 500 lM BH4 in the TnT
assays. (B) PAH activity of enzyme expressed in the TnT system in the absence and presence of the indicated concentrations of BH4. The values are
given relative to the activity of the control PAH synthesized in the absence of BH4 and are calculated in mU/cpm. Five mM dithiothreitol was present
in the reactions, whereby the reducing agent did not aﬀect the amount of PAH expressed or activity of the TnT mixtures, i.e., similar values in the
absence of BH4 and in the presence or absence of 5 mM dithiothreitol.
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were compromised for cofactor biosynthesis by harboring a
homozygous or heterozygous deletion allele for Pts. The Pts
gene codes for the second BH4-biosynthetic enzyme, the 6-
pyruvoyl-tetrahydropterin synthase [1]. Homozygous Pts=
mice generated by targeted deletion were born with no visible
developmental abnormalities, including normal liver, but died
soon after birth due to neurotransmitter deﬁciency [23]. As
previously reported, liver extracts of newborn wild-type mice
contain 21.06 0.43 pmol BH4 per mg of protein, whereas
heterozygous Pts-animals exhibit reduced BH4 levels
(12.53 0.60 pmol/mg) and Pts knockout mice have only
traces of liver BH4 (0.87 0.22 pmol/mg) [23]. We now com-
pared BH4 content to PAH gene expression and activity in the
liver of newborn mice (Fig. 2). The PAH activity of wild-type
animals was 1.05 0.14 mU/mg, and it was reduced to
0.62 0.04 mU/mg in heterozygous and to 34% that of the
wild-type mice in homozygous Pts knockout (0.36 0.07 mU/
mg; Fig. 2B). In contrast, mRNA levels for Pah, quantiﬁed
using real-time PCR technology, showed basically no diﬀer-
ence between liver samples of wild-type, heterozygous, and
knockout animals (see Fig. 2C; the relative values with respect
to GAPDH controls were: wild-type 2.49 1.49, range 1.18–
4.39; heterozygous 2.91 1.70, range 1.09–6.84, and knockout
2.30 1.03, range 1.0–3.62). Gene expression and/or mRNA
stability for the Pah gene was thus not responsible for the re-
duction of PAH activity.
We then determined the amount of PAH protein per total
protein in liver extracts by quantitative Western blot analysis
(Fig. 3). The wild-type mice had 1.8 0.63 lg PAH protein/mg,
while the heterozygous animals had 0.81 0.10 lg/mg, and the
knockout mice had 0.34 0.10 lg/mg. Thus, the PAH protein
represents 0.18% of the total liver protein in newborn wild-type
mice and this value was reduced to 0.034% for the knockout
animals. The PAH content in wild-type mice corresponds to
about 40 pmol of PAH subunit/mg total protein, and is similar
to the values reported in rat hepatocytes (i.e., 41.7 pmol PAH
subunit/mg protein, corresponding to 9.1 lM intracellular
PAH subunit [30] as well as to values reported in rat liver by
several other authors, where PAH represents 0.1–0.3% of the
total protein [31,32]. As can be seen in the representativeWestern blots (Fig. 3A), low molecular weight proteolyzed
forms of PAH were present in extracts from knockout animals
indicating that the low amounts of PAH protein and activity
PAH measured inPts= mice result from degradation of the
enzyme either in vivo or, less likely, during the quick prepara-
tion of the liver extracts. These results strongly suggest that the
amount of BH4 cofactor endogenously synthesized appears to
directly aﬀect the conformational stability and consequently
the activity of PAH, rather than by inﬂuencing PAH gene ex-
pression or mRNA stability. Earlier in vitro experiments
showed that the binding of BH4 induces a tighter conformation
of the enzyme and reduces the rate and extent of proteolytic
degradation of PAH both by trypsin [33] and chymotrypsin [6].
Our in vitro and in vivo results highlight the importance of
BH4 in preserving the enzymatic integrity of PAH. The eﬀect
appears to be dramatic as seen in the in vivo situation in the
absence of cofactor, but is still observed upon cofactor addi-
tion in the in vitro system. In this context, it is also worth
mentioning that Kaufman and coworkers observed in the liver
biopsy from a patient with PKU due to deﬁciency of dihy-
dropteridine reductase that the level of PAH was decreased to
about 20% of controls [29]. They further speculated that this
lack was due to BH4 deﬁciency which could lead to an accel-
erated rate of degradation of PAH, similar to what we ﬁnd
here in our BH4-deﬁcient mice. A somewhat similar observa-
tion was also made for tyrosine hydroxylase in BH4-deﬁcient
mice: the protein in the brain of homozygous newborn mice
was reduced in Western blots, whereas the mRNA levels ex-
hibited no diﬀerence, as shown by Northern blot analysis [22].
These observations might represent a more general in vivo
regulatory mechanism of BH4 at least for PAH and tyrosine
hydroxylase. However, it has to be stressed that tyrosine hy-
droxylase and dopamine biosynthesis in the brain of Pts=
mice were not recovered upon administration of BH4. On the
other hand, BH4 loading led to a reduction of blood phenyl-
alanine levels to normal serum conditions [22,23]. Further-
more, treating adult wild-type mice for 10 days with oral daily
doses of 10 mg of BH4 per kg body weight did not induce any
change neither in relative Pah-mRNA or PAH expression and
activity (not shown), an observation that was recently con-























































Fig. 2. Comparison of BH4 content (A), PAH activity (B), and Pah-mRNA expression (C) in liver extracts of one-day old mice with diﬀerent Pts
genotypes. Values in A and B are given per mg of total protein extract (p values for the Student’s t test are indicated; n¼ 3–6 measurements from at
least 3 diﬀerent animals per group). Note that BH4 values in A have been published previously ([23] in Table II) and are depicted here for comparison
to PAH expression. For TaqMan analysis in C, the liver from 6–8 individual animals was tested for Pah-mRNA expression in triplicates and given as
relative values compared to the GAPDH control.
Fig. 3. Quantiﬁcation of PAH in liver homogenates of one-day old
mice with diﬀerent Pts genotypes. Values are given per mg of total
protein extract. (A) Quantitative Western blot analyses. PAH stan-
dards; lanes 1, 2, 3 and 4: 100 ng, 25 ng, 6.3 ng, and 3.3 ng puriﬁed
human recombinant PAH [26]. Three ll of liver extract (about 30 mg
total protein/ml) was separated on the gels for the Pts wild-type, het-
erozygous and knockout mice. (B) Averaged quantitative data from
(A).
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PAH forms a low activity and high stability complex with
BH4 at metabolic stages characterized by low concentration of
L-Phe [30]. In turn, L-Phe is known to elicit an activating
conformational change on PAH that surpasses the closed
conformation induced by BH4 [4]. Formation of the PAH-BH4
complex appears to be an important regulatory mechanism
maintaining the integrity of the enzyme, and the lack of BH4would thus turn out to be deleterious for PAH, in agreement
with the results shown here. These results also seem to have
implications to understand the regulatory role of BH4 also in
disease situations, notably for BH4 responsiveness in a sub-
class of mild PKU patients. The PAHmutations leading to this
phenotype are spread throughout the 3D-structure [12]. A
common feature, however, is that the mutants are all charac-
terized by a considerable level, although insuﬃcient, of re-
maining PAH activity. The reason for why BH4
supplementation therapy is beneﬁcial might be related to the
fact that BH4 appears to be sub-saturating in vivo. Kure et al.
have recently discussed the implications of cofactor sub-satu-
ration, related to a lower hepatic concentration of BH4 (5–10
lM) with respect to the Km for the cofactor in the PAH re-
action (25 lM), to explain the increase in enzyme activity upon
supplementation [34]. Also relevant is our ﬁnding that BH4
appears to be sub-saturating with respect to PAH content in
order to form the stabilizing PAH-BH4 complex. Thus, wild-
type mice contain about half molar concentration of BH4 (21
pmol/mg protein) with respect to PAH (40 pmol PAH subunit/
mg protein) (see above). Mitnaul and Shiman [30] reported
stoichiometric amounts of cofactor and enzyme in rat he-
patocytes, while to our knowledge the values for this relation
are not known for human liver. Nevertheless, and because BH4
is also a cofactor for other liver enzymes, not all BH4 is ex-
pected to be available for complex formation with PAH and it
seems predictable that supplementation will further extend the
protective mechanisms that BH4 exerts on the enzyme as we
describe here and elsewhere, notably in non-homeostatic dis-
ease conditions, as PKU.
In conclusion, our results support that BH4 supplementation,
in addition to increase in PAH activity by increasing the sub-
saturating in vivo hepatic concentration of the cofactor [34], will
signiﬁcantly increase PAH activity by a rise in the amount of
B. Th€ony et al. / FEBS Letters 577 (2004) 507–511 511active and more stable enzyme that would reach the threshold
value for normal L-Phe hydroxylation levels in the patients.
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